Cyprotex PLC Cyprotex PLC - Rule 2.9 Announcement (3708M)

TIDMCRX

RNS Number : 3708M

Cyprotex PLC

13 October 2016

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

Cyprotex PLC

("Cyprotex" or "the Company")

Rule 2.9 Announcement - Relevant Securities in Issue

In accordance with Rule 2.9 of the Takeover Code, Cyprotex PLC, (AIM: CRX), confirms that it has the following securities in issue:

-- 22,509,042 Ordinary Shares of 1 pence each in issue at the close of business on 12 October 2016 and the Ordinary Shares in the Company are admitted to trading on AIM under the UK ISIN code GB00BP25RZ14; and

-- 4,584,645 of unsecured Convertible Loan Notes due in 30 September 2018 (the "Convertible Notes"). The Convertible Notes are convertible into Ordinary Shares in Cyprotex at a price of 60 pence per share. The Convertible Notes are admitted to the Official List of the Cayman Islands Stock Exchange under the International Securities Identification Number GB00BQ1XZQ04.

For further information:

 
 Cyprotex PLC                         Tel: [phone] 
                                       505 100 
 Dr Anthony Baxter, Chief Executive   [e-mail] 
  Officer                              www.cyprotex.com 
  John Dootson, Chief Financial 
  Officer 
  Mark Warburton, Chief Operating 
  Officer and Legal Counsel 
 
 N+1 Singer (Nomad, Broker & Rule     Tel: [phone] 
  3 Adviser to Cyprotex)               3000 
 Shaun Dobson                         [e-mail] 
  Jen Boorer                           [e-mail] 
                                       www.n1singer.com 
 Brown Gibbons Lang & Company         Tel: [phone] 
  (Financial Adviser to Cyprotex)      4774 
 John Riddle                          [e-mail] 
  J. Kyle Brown                        [e-mail] 
 

Notes to Editors

About Cyprotex PLC

Cyprotex is quoted on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1500 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company's core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr(R) toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe(R) PK, chemPK(TM) and chemTox, and a range of skin, ocular and endocrine disruption services. For more information, please visit www.cyprotex.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RTTGGGRUUUPQGGP

(END) Dow Jones Newswires

October 13, 2016 02:00 ET (06:00 GMT)